Ekso Bionics Holdings Inc
NASDAQ:EKSO
Intrinsic Value
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. [ Read More ]
The intrinsic value of one EKSO stock under the Base Case scenario is 1.78 USD. Compared to the current market price of 1.36 USD, Ekso Bionics Holdings Inc is Undervalued by 23%.
Valuation Backtest
Ekso Bionics Holdings Inc
Run backtest to discover the historical profit from buying and selling EKSO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ekso Bionics' Record-Revenue Growth and Efficiency
2023-Q4 Earnings Call
In 2023, Ekso Bionics achieved record annual revenues, hitting $18.3 million, a surge by 42% from 2022. This robust growth included a substantial 51% increase in EksoHealth devices sold, totaling 151 units. The fourth quarter alone saw revenues rise by 36% to $4.8 million, attributed to robust sales in EksoNR and Indego devices. Notably, the company launched GaitCoach software, expected to amplify utilization, and faced deferred payment determinations from CMS for its Indego Personal exoskeleton, promising ongoing efforts to secure a reimbursement rate. Internationally, sales soared across EMEA and APAC regions, with operational advancements such as the collaboration with high-volume manufacturers to lower costs. Despite revenue soaring, operating expenses grew only 11%, demonstrating impressive operational efficiency and a 3% inventory reduction.
Balance Sheet Decomposition
Ekso Bionics Holdings Inc
Current Assets | 20.2m |
Cash & Short-Term Investments | 8.6m |
Receivables | 5.6m |
Other Current Assets | 5.9m |
Non-Current Assets | 8.7m |
PP&E | 3m |
Intangibles | 5.3m |
Other Non-Current Assets | 392k |
Current Liabilities | 8.1m |
Accounts Payable | 1.8m |
Accrued Liabilities | 3m |
Other Current Liabilities | 3.2m |
Non-Current Liabilities | 8.2m |
Long-Term Debt | 4.8m |
Other Non-Current Liabilities | 3.4m |
Earnings Waterfall
Ekso Bionics Holdings Inc
Revenue
|
18.3m
USD
|
Cost of Revenue
|
-9.2m
USD
|
Gross Profit
|
9.1m
USD
|
Operating Expenses
|
-24.2m
USD
|
Operating Income
|
-15.1m
USD
|
Other Expenses
|
-86k
USD
|
Net Income
|
-15.2m
USD
|
Free Cash Flow Analysis
Ekso Bionics Holdings Inc
What is Free Cash Flow?
EKSO Profitability Score
Profitability Due Diligence
Ekso Bionics Holdings Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Ekso Bionics Holdings Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
EKSO Solvency Score
Solvency Due Diligence
Ekso Bionics Holdings Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Ekso Bionics Holdings Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EKSO Price Targets Summary
Ekso Bionics Holdings Inc
According to Wall Street analysts, the average 1-year price target for EKSO is 9.25 USD .
Ownership
EKSO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EKSO Price
Ekso Bionics Holdings Inc
Average Annual Return | -46.78% |
Standard Deviation of Annual Returns | 37.62% |
Max Drawdown | -98% |
Market Capitalization | 24.3m USD |
Shares Outstanding | 17 903 100 |
Percentage of Shares Shorted | 0.85% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in Richmond California, California and currently employs 45 full-time employees. The company went IPO on 2013-04-10. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The firm operates in two segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform repetitive work. Its products include EksoNR and EksoUE. EksoNR is a rehabilitation device that assists physical therapists and physicians to treat patients who have suffered an acquired brain injury, stroke or spinal cord injury. EksoUE is a wearable upper body exoskeleton that assists patients with a broad range of upper extremity impairments.
Contact
IPO
Employees
Officers
The intrinsic value of one EKSO stock under the Base Case scenario is 1.78 USD.
Compared to the current market price of 1.36 USD, Ekso Bionics Holdings Inc is Undervalued by 23%.